Skip to main
CNTA

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals PLC has a promising outlook due to its robust pipeline, specifically with the best-in-class potential of ORX750 for Narcolepsy Type 1, which could benefit from additional safety and efficacy data expected in early 2026. The company is financially well-positioned, having ended the second quarter of 2025 with approximately $405 million in cash, providing ample runway to support operations through mid-2027. Furthermore, the projected sales potential for ORX750 is estimated at around $3.6 billion, reflecting substantial upside potential from the pipeline's advancement and anticipated data outcomes.

Bears say

Centessa Pharmaceuticals's stock outlook is negatively impacted by concerns surrounding the high non-responder rates and late-day waning efficacy observed in related clinical programs, which may indicate broader issues within the OX2R class of treatments rather than being isolated to specific compounds. The Phase 2 data from the company reveals significant variability and potential suboptimal dose selection, further complicating the reliability of reported therapeutic effects and raising the probability of variable outcomes in real-world applications. Additionally, the inclusion of data from competing products appears to diminish the dose-response estimates for ORX750, raising further doubts about the potential of Centessa's pipeline assets in delivering anticipated results.

CNTA has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 10 analysts, CNTA has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.